MGNX
MacroGenics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.40
+3.53%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
Market Cap
$280.28M
MomentumView details →
1D Return
+3.53%
YTD Return
+167.39%
RSI (14)
56.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
Market Cap
$280.28M
RSI (14)
56.5
MomentumView details →
1D Return
+3.53%
YTD Return
+167.39%
SummaryUpdated Jun 1, 2026
MacroGenics, Inc. (NASDAQ:MGNX) is a biopharmaceutical company founded in 2000 and headquartered in Rockville, Maryland. The company went public in October 2013 and specializes in developing and commercializing antibody-based therapeutics for cancer treatment. MacroGenics has successfully brought two FDA-approved medicines to market: MARGENZA for HER2-positive breast cancer and TZIELD for type 1 diabetes prevention. The company operates primarily through its proprietary DART (Dual-Affinity Re-Targeting) platform technology, which enables the creation of novel bispecific antibodies and antibody-drug conjugates (ADCs) designed to enhance immune system targeting of cancer cells.
Similar companies
Latest newsMore news →
MacroGenics, Inc. reported its financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and pipeline progress.22d agoGilead Sciences exercised its option to exclusively license a preclinical bispecific program from MacroGenics under their 2022 collaboration agreement, triggering a $10 million payment to MacroGenics.24d ago